Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.

Huy X NgoAva Y XuGustavo E VelásquezNan ZhangVincent K ChangEkaterina V KurbatovaWilliam C WhitworthErin SizemoreKia BryantWendy CarrMarc WeinerKelly E DooleyMelissa EngleSusan E DormanPayam NahidSusan SwindellsRichard E ChaissonPheona NsubugaMadeleine LourensRodney DawsonRadojka M Savic

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)

Flat-dosing of rifampicin at 600 mg daily may be a reasonable alternative to the incumbent weight-banded dosing strategy for the standard-of-care 6-month regimen. Future research should assess the optimal dosing strategy for rifampicin, at doses higher than the current recommendation.

Keyphrases

mycobacterium tuberculosis
pulmonary tuberculosis
physical activity
palliative care
quality improvement
current status
hiv aids
pain management
chronic pain
hiv infected
antiretroviral therapy